博拓生物2024年归母净利润增59%至1.7亿元

财中社2025-04-27

4月25日，博拓生物(688767)公布2024年年报，公司营业收入为5.59亿元，同比上升26.5%；归母净利润为1.7亿元，同比上升59%；扣非归母净利润为1.19亿元，同比上升50.2%；经营现金流净额为1.29亿元，同比下降1.9%；EPS(全面摊薄)为1.5892元。其中第四季度，公司营业收入为1.71亿元，同比上升31.4%；归母净利润为8030万元，同比上升432.6%；扣非归母...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2530851304?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-27 13:56","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2530851304","market":"sh","top_or_hot":-1,"title":"博拓生物2024年归母净利润增59%至1.7亿元","media":"财中社","content":"<div>\n<p>4月25日，博拓生物(688767)公布2024年年报，公司营业收入为5.59亿元，同比上升26.5%；归母净利润为1.7亿元，同比上升59%；扣非归母净利润为1.19亿元，同比上升50.2%；经营现金流净额为1.29亿元，同比下降1.9%；EPS(全面摊薄)为1.5892元。其中第四季度，公司营业收入为1.71亿元，同比上升31.4%；归母净利润为8030万元，同比上升432.6%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042713571397470a8d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>博拓生物2024年归母净利润增59%至1.7亿元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n博拓生物2024年归母净利润增59%至1.7亿元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-27 13:56 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042713571397470a8d&s=b><strong>财中社</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>4月25日，博拓生物(688767)公布2024年年报，公司营业收入为5.59亿元，同比上升26.5%；归母净利润为1.7亿元，同比上升59%；扣非归母净利润为1.19亿元，同比上升50.2%；经营现金流净额为1.29亿元，同比下降1.9%；EPS(全面摊薄)为1.5892元。其中第四季度，公司营业收入为1.71亿元，同比上升31.4%；归母净利润为8030万元，同比上升432.6%；扣非归母...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042713571397470a8d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688767","symbol_name":"博拓生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042713571397470a8d&s=b","article_id":"2530851304","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042713571397470a8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2530851304","pubTimestamp":1745733376,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"4月25日，博拓生物公布2024年年报，公司营业收入为5.59亿元，同比上升26.5%；归母净利润为1.7亿元，同比上升59%；扣非归母净利润为1.19亿元，同比上升50.2%；经营现金流净额为1.29亿元，同比下降1.9%；EPS为1.5892元。其中第四季度，公司营业收入为1.71亿元，同比上升31.4%；归母净利润为8030万元，同比上升432.6%；扣非归母净利润为3814万元，同比上升968.5%；EPS为0.7528元。截至四季度末，公司总资产26.02亿元，较上年度末增长0.9%；归母净资产为24.09亿元，较上年度末下降0.2%。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"688767":"博拓生物"},"translate_title":"Botuo Biotech's net profit attributable to the parent company will increase by 59% to 170 million yuan in 2024","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688767":1},"content_text":"4月25日，博拓生物(688767)公布2024年年报，公司营业收入为5.59亿元，同比上升26.5%；归母净利润为1.7亿元，同比上升59%；扣非归母净利润为1.19亿元，同比上升50.2%；经营现金流净额为1.29亿元，同比下降1.9%；EPS(全面摊薄)为1.5892元。其中第四季度，公司营业收入为1.71亿元，同比上升31.4%；归母净利润为8030万元，同比上升432.6%；扣非归母净利润为3814万元，同比上升968.5%；EPS为0.7528元。截至四季度末，公司总资产26.02亿元，较上年度末增长0.9%；归母净资产为24.09亿元，较上年度末下降0.2%。公司在2024年度报告中对其经营业务的重大变动进行了详细的讨论与分析。报告指出，2024年是公司在全面落实党的政策和推动产品创新的重要一年，面对复杂的全球产业链环境，公司依靠全体员工的团结协作，成功推出了多项核心研发项目，并实现了市场化应用。在经营策略方面，公司聚焦渠道效能的升级，通过线上线下的协同营销网络，提升了品牌价值与市场覆盖率。此外，公司强化了合规保障体系，顺利完成多款新产品的上市审批，并在智能制造体系的革新中，通过精益管理和智能化改造，提升了生产效能与质量标准，为公司的高质量发展奠定了基础。报告还提到，公司在微流控技术平台的建设上取得了显著进展，推出了多款新型检测试剂和免疫层析分析仪，进一步巩固了在药物滥用检测和传染病检测等核心产品线的市场地位。整体来看，公司的业务组合在不断扩展，抗风险能力显著增强，展现出良好的发展势头。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2530851304","isCrawlerRequest":true}